P1, N=6, Completed, Merck Sharp & Dohme LLC

P1, N=34, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed

P2, N=224, Completed, Merck Sharp & Dohme LLC | Phase classification: P2a --> P2

P1/2, N=50, Active, not recruiting, MediciNova | Trial completion date: Jun 2024 --> Dec 2024

P2, N=36, Completed, MediciNova | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Aug 2024

P1, N=32, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting

P2, N=180, Recruiting, Noema Pharma AG | Not yet recruiting --> Recruiting | Initiation date: May 2024 --> Sep 2024

P2, N=120, Recruiting, VA Office of Research and Development | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Jun 2025

P2, N=500, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed

P2, N=189, Completed, Celon Pharma SA | Recruiting --> Completed

P2, N=18, Completed, Noema Pharma Australia Pty Ltd | Recruiting --> Completed | N=10 --> 18

P2, N=108, Recruiting, Celon Pharma SA | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Nov 2024

P1, N=76, Completed, BenevolentAI Bio | Recruiting --> Completed

P1, N=32, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting

P2/3, N=230, Recruiting, MediciNova | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025

P2, N=500, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting

P2, N=180, Not yet recruiting, Noema Pharma AG

P2/3, N=230, Recruiting, MediciNova | Trial primary completion date: Dec 2023 --> Dec 2024

P1/2, N=50, Active, not recruiting, MediciNova | Phase classification: P1b/2a --> P1/2

P2, N=75, Completed, Noema Pharma AG | Active, not recruiting --> Completed

P1, N=107, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed

P1, N=32, Not yet recruiting, Merck Sharp & Dohme LLC

P2, N=165, Recruiting, Celon Pharma SA | Trial completion date: Nov 2023 --> Apr 2024 | Trial primary completion date: Oct 2023 --> Mar 2024

P2, N=108, Recruiting, Celon Pharma SA | Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: Nov 2023 --> Jun 2024

P1, N=84, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting

P2, N=120, Recruiting, VA Office of Research and Development | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2024

P2, N=67, Active, not recruiting, Noema Pharma AG | Phase classification: P2b --> P2

P2/3, N=230, Recruiting, MediciNova | Phase classification: P2b --> P2/3

P2, N=500, Recruiting, Merck Sharp & Dohme LLC | Phase classification: P2b --> P2

CD3 expression was a good predictor for tumor progression for five months in recurrent GBM patients treated with MN-166 and TMZ. T cell infiltration within GBM tumors has been an active area of research with the success of immune checkpoint blockade (ICB) therapies in other cancers. Moreover, MN-166 has been shown to impact immune suppressive myeloid cells, which are linked to the immune suppressive tumor microenvironment and a resistance mechanism to ICB.

P1, N=108, Recruiting, BenevolentAI Bio

In conclusion, our findings suggested that inhibition of CXCR2 promoted OPC differentiation and enhanced remyelination by regulating PDE10A/cAMP/ERK1/2 signaling pathway. The present data also highlighted that CXCR2 may serve as a potential target for the treatment of demyelination diseases.

More insight into the effects of the compound on cellular and molecular mechanisms is needed. Understanding the effects PPV may exert on tumorigenic cells may better researchers' understanding of phytomedicines and the effects of PPV and PPV-derived compounds in cancer.

Using small molecule inhibitors, Pf-2545920 and a novel NSAID-derived PDE10A inhibitor, MCI-030, we show that PDE10A inhibition leads to decreased ovarian cancer cell growth and induces cell cycle arrest and apoptosis...We also demonstrate that PDE10A inhibition leads to decreased Wnt-induced β-catenin nuclear translocation, as well as decreased EGF-mediated activation of RAS/MAPK and AKT pathways in ovarian cancer cells. These findings implicate PDE10A as novel target for ovarian cancer chemoprevention and treatment.

In particular, a combination comprising the MRP1 inhibitor reversan, PF-2545920 and MY-5445, all at low micromolar concentrations, afforded nearly complete inhibition of glioblastoma cell growth. Thus, the potent suppression of glioblastoma cell viability may be achieved by combining MRP1 inhibitors with PDE inhibitors at a lower toxicity than that of the standard chemotherapeutic agents, thereby providing a new combination therapy for this challenging malignancy.

Here we describe a novel non-cyclooxygenase inhibitory derivative of the anti-inflammatory drug, sulindac, with selective PDE10 inhibitory activity, ADT 061...Oral administration of ADT 061 resulted in high concentrations in the colon mucosa and significantly suppressed the formation of colon adenomas in the Apc+/min-FCCC mouse model of colorectal cancer (CRC) without discernable toxicity. These results support the development of ADT 061 for the treatment or prevention of adenomas in individuals at risk of developing CRC.

Infrequently, cases of tumors with IFS-like morphology without the characteristic ETV6-NTRK3 gene fusion have been identified. Herein, an ETV6-NTRK3 fusion negative spindle cell sarcoma with IFS-like morphology subjected to genomic profiling revealed a PDE10A-BRAF fusion, a fusion event that has been detected previously in an isolated case of undifferentiated infantile sarcoma.

Upon extending the analysis to a cell-type specific level, some of these common molecular players were selectively expressed in excitatory neurons, oligodendrocytes, and endothelial cells. Overall, computational analysis of publicly available whole transcriptome datasets provides new insights into the molecular basis of addiction-like behaviors in PFC.

Ancestry proportion results for African, European, and Indigenous American were 24.1%, 64.2%, and 11.7%, respectively. The identification of DNA methylation patterns related to PCa in H/L men along with specific patterns related to aggressiveness and DNA repair constitutes a pivotal effort for the understanding of PCa in this population.

The identification of DNA methylation patterns related to PCa in Puerto Rican (PR) H/L men along with specific patterns related to aggressiveness and DNA repair constitutes a pivotal effort on the understanding of PCa disparities in this population. This constitutes a unique effort to provide an overview regarding methylation and ancestry patterns in PR H/L men.